Multiple Sclerosis is the first cause of neurological handicap in France. The importance of cognitive disabilities, their evaluation and their impact on patients' life have only been comprehended recently. Immunosuppressants represent new treatments in Multiple Sclerosis (MS) but imply a lot of constraints. This study will evaluate the impact of these treatments on cognitive disabilities, tiredness state, emotion and quality of life in general, on a lengthened period.
Multiple Sclerosis is the first cause of neurological handicap in France. The importance of cognitive disabilities, their evaluation and their impact on patients' life have only been comprehended recently. Immunosuppressants represent new treatments in MS but imply a lot of constraints. This study will evaluate the impact of these treatments on cognitive disabilities, tiredness state, emotion and quality of life in general, on a lengthened period.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
OTHER
Masking
NONE
Enrollment
48
This study will evaluate the impact of these treatments on cognitive disabilities, tiredness state, emotion and quality of life in general, on a lengthened period.
CHU Clermont-Ferrand
Clermont-Ferrand, France
Evolution of the quality of life of patients diagnosed with relapsing MS and starting a treatment with immunosuppressant
Time frame: on a 36 months period
Analysis of variance for repeated measurement
Time frame: 15 to 30 days before the beginning of treatment, after 36 months
Selective Reminding Test (SRT)
Time frame: 15 to 30 days before the beginning of treatment, 1st day of treatment, after 18 and 36 months
Delayed recall of SRT
Time frame: 15 to 30 days before the beginning of treatment, 1st day of treatment, after 18 and 36 months
Visuo-spatial span
Time frame: 15 to 30 days before the beginning of treatment, 1st day of treatment, after 18 and 36 months
Digit span
Time frame: 15 to 30 days before the beginning of treatment, 1st day of treatment, after 18 and 36 months
Reverse span
Time frame: 15 to 30 days before the beginning of treatment, 1st day of treatment, after 18 and 36 months
Stroop test
Time frame: 15 to 30 days before the beginning of treatment, 1st day of treatment, after 18 and 36 months
• Tiredness (EMIF SEP scale): Analysis of variance for repeated measurement
Time frame: 15 to 30 days before the beginning of treatment, 1st day of treatment, after 6,12,18 and 36 months
• Physical function (9HPT, 8 meter walk) : Analysis of variance for repeated measurement
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Time frame: 15 to 30 days before the beginning of treatment, 1st day of treatment, after 6,12,18 and 36 months
Disability (EDSS) : Analysis of variance for repeated measurement
Time frame: 15 to 30 days before the beginning of treatment, 1st day of treatment, after 6,12,18 and 36 months
• Psychological disorder (Beck depression inventory, COVI scale, Depressive scale) : Analysis of variance for repeated measurement
Time frame: 15 to 30 days before the beginning of treatment, 1st day of the treatment, after 6,12,18 and 36 months